Genes (27)
Species: human : 27 | |
Human | SP7 | 121340 | Sp7 transcription factor | INFERRED, Score=800, UMLKSK CUI: C0017525 | Human | C1QTNF3 | 114899 | C1q and tumor necrosis factor related protein 3 | Therefore, a human bone tumor cDNA panel was investigated and a strong CORS-26 mRNA expression was found in osteosarcoma, chondroblastoma and giant cell tumor. | Human | USP6 | 9098 | ubiquitin specific peptidase 6 (Tre-2 oncogene) | CDH11 and USP6 rearrangements were not found in any of 17 secondary ABC associated with giant cell tumor, chondroblastoma, osteoblastoma, and fibrous dysplasia. | Human | TNFRSF11A | 8792 | tumor necrosis factor receptor superfamily, member 11a, NFKB activator | INFERRED, Score=800, UMLKSK CUI: C0017525 | Human | TP63 | 8626 | tumor protein p63 | p63 may be a useful biomarker to differentiate giant cell tumor of bone from central giant cell granuloma and other giant cell-rich tumors | Human | TNFSF11 | 8600 | tumor necrosis factor (ligand) superfamily, member 11 | OBJECTIVE: To investigate the gene expression of osteoprotegerin (OPG) and osteoclast differentiation factor (ODF/TRANCE/RANKL), two new members of the TNF-receptor superfamily, in giant cell tumor (GCT); to discuss the molecular mechanism of extensive bone resorption caused by GCT. The giant cell tumors as well as stromal cell cultures derived from giant cell tumors express osteoprotegerin ligand, the osteoclast activator. Expression of RANKL mRNA and protein were determined in the developmental progression of endochondral bone formation in mouse, intramembranous bone formation in a rabbit model (mRNA only), in human giant cell tumors of bone, and at extraskeletal sites in the mouse. We recently showed that the stromal cells of osteolytic giant cell tumors (GCT) of bone express high levels of mRNA encoding RANKL, relative to mRNA for the RANKL antagonist, OPG, compared with the expression patterns of other lytic and nonlytic bone tumors. Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor. | Human | FGF23 | 8074 | fibroblast growth factor 23 | Expression of both FGF23 mRNA and protein was demonstrated in the giant cell tumor tissue, and FGF23 mRNA expression and renal phosphate uptake inhibitory activity were also detected in cultured giant cell tumor cells. Positive staining for FGF23 protein by immunohistochemistry was demonstrated in the giant cell tumor, but not in the angiolipoma. The serum concentration of FGF23 was elevated in preoperative serum, then normalized after removal of the giant cell tumor. | Human | ADAM12 | 8038 | ADAM metallopeptidase domain 12 | CONCLUSIONS: These results indicate that multinucleated giant cells are formed by the cell fusion of mononuclear stromal cells in giant cell tumours of bone and that ADAM12 is involved in the cell fusion process. The expression of ADAM12 (meltrin alpha) in human giant cell tumours of bone. AIMS: To examine the expression of ADAM12 (meltrin alpha), a member of the disintegrin and metalloprotease (ADAM) family, in human giant cell tumours of the bone, skeletal muscle tissue from human embryos, and human adult skeletal muscle tissue. RESULTS: ADAM12 mRNA was detected in 14 of the 20 giant cell tumours of bone and in three of the six tumour cell cultures. | Human | TERT | 7015 | telomerase reverse transcriptase | reverse transcriptase expression may predict recurrence in giant-cell tumor | Human | SRC | 6714 | v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog | Results suggest that c-Src may be involved in the formation of giant cells in cherubism, central giant cell granuloma and giant cell tumors | Human | PDGFB | 5155 | platelet-derived growth factor beta polypeptide | A normal 3.7-kb c-sis transcript was expressed at a low level in most of the sarcomas and the melanoma but was uniquely overexpressed in giant cell tumors of bone. | Human | TNFRSF11B | 4982 | tumor necrosis factor receptor superfamily, member 11b | Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor. We recently showed that the stromal cells of osteolytic giant cell tumors (GCT) of bone express high levels of mRNA encoding RANKL, relative to mRNA for the RANKL antagonist, OPG, compared with the expression patterns of other lytic and nonlytic bone tumors. OBJECTIVE: To investigate the gene expression of osteoprotegerin (OPG) and osteoclast differentiation factor (ODF/TRANCE/RANKL), two new members of the TNF-receptor superfamily, in giant cell tumor (GCT); to discuss the molecular mechanism of extensive bone resorption caused by GCT. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. | Human | NME1 | 4830 | NME/NM23 nucleoside diphosphate kinase 1 | This immunohistochemical test for nm23 is easily performed on standard paraffin sections and is recommended as an accurate prognostic marker for giant cell tumours of tendon sheath. Giant cell tumours of the tendon sheath: lack of correlation between nm23-H1 expression and recurrence. The aim of this study was to investigate the expression of nm23 in a series of 52 giant cell tumours using immunohistochemistry and to assess its prognostic potential. nm23 expression was absent in 21%, of tumours and this was associated with a highly significant risk of local recurrence (P_lt_0.0001). The aim of this study was to investigate the expression of nm23 in a series of 52 giant cell tumours using immunohistochemistry and to assess its prognostic potential. RESULT: The expression of nm23-H1 in 4 cases of primary giant cell tumor (GCT) was high, but was low or absent in 3 recurrent ones. RESULT: The expression of nm23-H1 in 4 cases of primary giant cell tumor (GCT) was high, but was low or absent in 3 recurrent ones. Giant cell tumours of the tendon sheath: lack of correlation between nm23-H1 expression and recurrence. | Human | MET | 4233 | met proto-oncogene | In this study, we analyzed 40 biopsy samples of a collection of giant cell tumors and other rare benign tumors of bone for expression of the MET proto-oncogene. | Human | HLA-DRB1 | 3123 | | Association of HLA-DRB1 alleles with giant cell tumour of bone. | Human | GRID2 | 2895 | glutamate receptor, ionotropic, delta 2 | In subependymal giant-cell tumors, tumor cells also exhibited consistent immunoreactivity to vimentin but only faint immunoreactivity to GluR 2(3). | Human | FLI1 | 2313 | Fli-1 proto-oncogene, ETS transcription factor | No EWS/FLI1 fusion transcripts in giant-cell tumors of bone. | Human | CTSK | 1513 | cathepsin K | Furthermore, the expression of cathepsin K mRNA in giant cell tumor tissue appeared to be confined to the periphery of the osteoclast indicating a compartmentalization of the mRNA. Since cathepsins are proposed to be involved in the degradation of mineralized bone matrix, we have investigated, by in situ hybridization and immunocytochemistry, the expression of the cathepsin K mRNA transcripts and protein in sections of bone and giant cell tumor to determine which cells express this enzyme. | Human | CDH11 | 1009 | cadherin 11, type 2, OB-cadherin (osteoblast) | CDH11 and USP6 rearrangements were not found in any of 17 secondary ABC associated with giant cell tumor, chondroblastoma, osteoblastoma, and fibrous dysplasia. | Human | CD68 | 968 | CD68 molecule | Transforming growth factor alpha and CD68 immunoreactivity in giant cell tumours of bone: a study on the nature of stromal and giant cells, and their interrelations. | Human | CD36 | 948 | CD36 molecule (thrombospondin receptor) | Using RT-PCR and immunoblotting, we further demonstrate expression of CD36 in human osteoclastoma (giant cell tumour), primary human bone derived cells, and clonal osteoblastic cells. | Human | CALCR | 799 | calcitonin receptor | INFERRED, Score=800, UMLKSK CUI: C0017525 | Human | BSG | 682 | basigin (Ok blood group) | EMMPRIN may be an important regulatory factor involved in the biological behaviors of giant cell tumor | Human | BMP6 | 654 | bone morphogenetic protein 6 | Transforming growth factor-beta (TGF-beta) is released from the matrix during bone resorption and has been implicated in the pathogenesis of giant cell tumors of bone and the expansion of breast cancer metastases in bone. | Human | AMFR | 267 | autocrine motility factor receptor, E3 ubiquitin protein ligase | Giant cell tumors of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. |
|